148 citations
,
March 2022 in “The New England Journal of Medicine” In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.
13 citations
,
November 2021 in “Pediatric Dermatology” This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.
66 citations
,
June 2021 in “Journal of The American Academy of Dermatology” In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.
57 citations
,
March 2021 in “International Journal of Molecular Sciences” This study found that type 2 immunity may play a role in the development of alopecia areata in patients with extrinsic atopic dermatitis, indicating different immunological states compared to non-atopic patients.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” This study observed that some children and young adults with alopecia areata experienced flares during long-term tofacitinib treatment, despite initial successful hair regrowth.
26 citations
,
October 2020 in “Pediatric Dermatology” This study found that oral tofacitinib led to clinically significant improvement in alopecia areata severity scores among pre-adolescents, though results varied and further evaluation in clinical trials is needed.
37 citations
,
December 2019 in “Giornale italiano di dermatologia e venereologia” This Italian guideline discusses the diagnosis and treatment of alopecia areata but reports no new clinical trial results; the authors highlight the need for well-designed studies.
11 citations
,
November 2019 in “Clinical Case Reports” This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.
29 citations
,
July 2019 in “Dermatologic Therapy” This report describes two patients with atopic dermatitis receiving dupilumab, where one experienced healing of alopecia areata and the other developed it, illustrating the drug's varied effects.
32 citations
,
April 2019 in “JAAD case reports” This study discusses the immune dysregulation observed in individuals with Down syndrome, highlighting their increased risk for autoimmune skin conditions, but does not yet clarify the molecular mechanisms behind this profile.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” In this study, three children with severe alopecia treated with systemic tofacitinib showed significant hair regrowth, suggesting it may be a potential option for those unresponsive to conventional therapy.
37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” This letter discusses the emerging use of Janus kinase inhibitors, specifically oral tofacitinib, for treating alopecia areata in children, but reports no new clinical findings.
5 citations
,
August 2018 in “PubMed” This case report documented successful full hair regrowth in an 8-year-old with alopecia universalis after oral tofacitinib treatment, but mild headaches led to discontinuation.
49 citations
,
May 2018 in “Journal of the American Academy of Dermatology” This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.
83 citations
,
June 2017 in “Journal of the American Academy of Dermatology” This study observed that most pediatric patients with alopecia areata experienced some hair regrowth after treatment with topical JAK inhibitors, and the formulations were generally well-tolerated with mild lab abnormalities in some cases.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.
144 citations
,
July 2015 in “Clinical, Cosmetic and Investigational Dermatology” This review reports that alopecia areata affects about 2% of people globally and is linked with psychiatric and medical comorbidities, highlighting its significant disease burden.
184 citations
,
February 2015 in “EBioMedicine” This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.
701 citations
,
August 2014 in “Nature medicine” This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.
218 citations
,
April 2012 in “British Journal of Dermatology” This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.
